Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of alterations that go from simple steatosis to steatohepatitis and cirrhosis. Type 2 diabetes mellitus (DM-2) and obesity are the principle factors associated to NAFLD. A 20-30 % prevalence in general population has been described. The survival of this type of patient is lower than the general population's, showing a higher incidence of hepatic and cardiovascular complications. The aetiopathogenesis is still unclear, but we know the intervention of different factors that produce fatty-acid accumulation in hepatic parenchyma, causing oxidative stress, oxygen-free radicals and the synthesis of an inflammatory cascade, that determine the progression of this disease from steatosis up to advanced fibrosis. The diagnostic gold-standard is still the liver biopsy, even though the development of newer non-invasive techniques, like serological and imaging (radiology), have opened a new field for research that allows bloodless testing of these patients and better study of the natural history of this disease. Nowadays, there is still no specific treatment for NAFLD. The development of healthy life habits and moderate exercise continue to be the pillars of treatment. Different pharmacological approaches have been studied and applied, such as the control of insulin resistance, lowering cholesterol levels, antioxidants, and other alternatives in experimental trials.

Saved in:
Bibliographic Details
Main Authors: Martín-Domínguez,Verónica, González-Casas,Rosario, Mendoza-Jiménez-Ridruejo,Jorge, García-Buey,Luisa, Moreno-Otero,Ricardo
Format: Digital revista
Language:English
Published: Sociedad Española de Patología Digestiva 2013
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000700006
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1130-01082013000700006
record_format ojs
spelling oai:scielo:S1130-010820130007000062013-12-09Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver diseaseMartín-Domínguez,VerónicaGonzález-Casas,RosarioMendoza-Jiménez-Ridruejo,JorgeGarcía-Buey,LuisaMoreno-Otero,Ricardo Steatosis Steatohepatitis Fibrosis Non-alcoholic fatty liver disease (NAFLD) Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of alterations that go from simple steatosis to steatohepatitis and cirrhosis. Type 2 diabetes mellitus (DM-2) and obesity are the principle factors associated to NAFLD. A 20-30 % prevalence in general population has been described. The survival of this type of patient is lower than the general population's, showing a higher incidence of hepatic and cardiovascular complications. The aetiopathogenesis is still unclear, but we know the intervention of different factors that produce fatty-acid accumulation in hepatic parenchyma, causing oxidative stress, oxygen-free radicals and the synthesis of an inflammatory cascade, that determine the progression of this disease from steatosis up to advanced fibrosis. The diagnostic gold-standard is still the liver biopsy, even though the development of newer non-invasive techniques, like serological and imaging (radiology), have opened a new field for research that allows bloodless testing of these patients and better study of the natural history of this disease. Nowadays, there is still no specific treatment for NAFLD. The development of healthy life habits and moderate exercise continue to be the pillars of treatment. Different pharmacological approaches have been studied and applied, such as the control of insulin resistance, lowering cholesterol levels, antioxidants, and other alternatives in experimental trials.Sociedad Española de Patología DigestivaRevista Española de Enfermedades Digestivas v.105 n.7 20132013-08-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000700006en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Martín-Domínguez,Verónica
González-Casas,Rosario
Mendoza-Jiménez-Ridruejo,Jorge
García-Buey,Luisa
Moreno-Otero,Ricardo
spellingShingle Martín-Domínguez,Verónica
González-Casas,Rosario
Mendoza-Jiménez-Ridruejo,Jorge
García-Buey,Luisa
Moreno-Otero,Ricardo
Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
author_facet Martín-Domínguez,Verónica
González-Casas,Rosario
Mendoza-Jiménez-Ridruejo,Jorge
García-Buey,Luisa
Moreno-Otero,Ricardo
author_sort Martín-Domínguez,Verónica
title Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
title_short Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
title_full Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
title_fullStr Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
title_full_unstemmed Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
title_sort pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
description Non-alcoholic fatty liver disease (NAFLD) includes a broad spectrum of alterations that go from simple steatosis to steatohepatitis and cirrhosis. Type 2 diabetes mellitus (DM-2) and obesity are the principle factors associated to NAFLD. A 20-30 % prevalence in general population has been described. The survival of this type of patient is lower than the general population's, showing a higher incidence of hepatic and cardiovascular complications. The aetiopathogenesis is still unclear, but we know the intervention of different factors that produce fatty-acid accumulation in hepatic parenchyma, causing oxidative stress, oxygen-free radicals and the synthesis of an inflammatory cascade, that determine the progression of this disease from steatosis up to advanced fibrosis. The diagnostic gold-standard is still the liver biopsy, even though the development of newer non-invasive techniques, like serological and imaging (radiology), have opened a new field for research that allows bloodless testing of these patients and better study of the natural history of this disease. Nowadays, there is still no specific treatment for NAFLD. The development of healthy life habits and moderate exercise continue to be the pillars of treatment. Different pharmacological approaches have been studied and applied, such as the control of insulin resistance, lowering cholesterol levels, antioxidants, and other alternatives in experimental trials.
publisher Sociedad Española de Patología Digestiva
publishDate 2013
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082013000700006
work_keys_str_mv AT martindominguezveronica pathogenesisdiagnosisandtreatmentofnonalcoholicfattyliverdisease
AT gonzalezcasasrosario pathogenesisdiagnosisandtreatmentofnonalcoholicfattyliverdisease
AT mendozajimenezridruejojorge pathogenesisdiagnosisandtreatmentofnonalcoholicfattyliverdisease
AT garciabueyluisa pathogenesisdiagnosisandtreatmentofnonalcoholicfattyliverdisease
AT morenooteroricardo pathogenesisdiagnosisandtreatmentofnonalcoholicfattyliverdisease
_version_ 1755938648042242048